PLx Pharma Inc. (NASDAQ:PLXP) Files An 8-K Regulation FD Disclosure

Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1
to comply with Regulation FD. Such information shall not be
deemed to be filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, and shall not be deemed to be
incorporated by reference into any of the Companys filings under
the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, whether made before or after
the date hereof and regardless of any general incorporation
language in such filings, except to the extent expressly set
forth by specific reference in such a filing.

Item 8.01 Other Events.

to the Merger Agreement, AcquireCo merged with and into PLx, with
PLx surviving the Merger and becoming a wholly owned subsidiary
of the Company. The Merger has been accounted for as a reverse
acquisition business combination, with PLx treated as the
accounting acquirer of the Company. Following Financial
Accounting Standards Boardguidance related to the accounting for
reverse acquisitions, PLxs historical financial statements will
replace the Companys historical financial statements.
Accordingly, the capital structure, and per share amounts
presented in PLxs historical financial statements for the periods
immediately prior to the Merger have been recast to reflect the
capitalization in accordance with the exchange ratio established
in the Merger. PLxs historical consolidated financial statements
as of and for the years ended December 31, 2016 and 2015 and for
the three-month periods ended March 31, 2017 and 2016, reflecting
the recasting, are attached as Exhibits 99.2 and 99.3 hereto and
are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

About PLx Pharma Inc. (NASDAQ:PLXP)

PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

PLx Pharma Inc. (NASDAQ:PLXP) Recent Trading Information

PLx Pharma Inc. (NASDAQ:PLXP) closed its last trading session down -0.27 at 6.68 with 15,737 shares trading hands.